{"entity":{"id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","aka":[],"tldr":"A phase 2 trial of YL201 in prostate cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC is a phase 2 interventional study registered as NCT06241846 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2024-02-22 and due to reach its primary completion in 2027-02. Interventions recorded: YL201 for Injection. Conditions listed: Metastatic Castration-resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06241846","url":"https://clinicaltrials.gov/study/NCT06241846"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["yl201"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06241846","phase":"2","setting":"A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct06241846/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}